Epiboxidine 

Epiboxidine is a potent and selective neural nAChR agonist with K_is of 0.46 nM and 1.2 nM for rat and human α4β2 nAChRs, respectively. Epiboxidine is a methylisoxazole analog of the alkaloid Epibatidine, and is also an analog of another nAChR agonist, ABT 418^[1].

Ki: 0.46 nM (rat α4β2 nAChR) and 1.2 nM (human α4β2 nAChR)^[1]

Epiboxidine has affinity and functional at central neuronal α4β2 receptors, with K_is of 0.46 and 1.2 in rat and humen^[1].
Epiboxidine has activity at ganglionic-type α3β4*-nicotinic receptors of PC12 cells, with a K_i of 19^[1].
Epiboxidine is much less toxic than Epibatidine^[1].
Epiboxidine stimulates sodium-22 influx in PC12 and TE671 cells, with EC₅₀s of 0.18 and 2.6 µM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Epiboxidine (20 μg/kg; ip; once) treatment shows marked analgetic activity in mice^[1].
Epiboxidine (50 and 100 mg/kg; intraperitoneal injected; once) causes marked antinociception as measured in the hot-plate assay^[2].
Epiboxidine inhibits [³H]nicotine binding in rat cerebral cortical membranes, with a K_i of 0.6 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

178.23

C₁₀H₁₄N₂O

188895-96-7

CC1=NOC([C@@H]2[C@@H]3N[C@@H](CC3)C2)=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fitch RW, et al. Homoepiboxidines: further potent agonists for nicotinic receptors. Bioorg Med Chem. 2004;12(1):179-190.  [Content Brief]

  [2]. Badio B, et al. Synthesis and nicotinic activity of epiboxidine: an isoxazole analogue of epibatidine. Eur J Pharmacol. 1997;321(2):189-194.  [Content Brief]